Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):341-346. doi: 10.3760/cma.j.cn112138-20200304-00179.
Multiple myeloma (MM) is a clonal plasma cell disorder, the second most hematological malignancy. MM mainly develops in elderly people and remains incurable at present. With the development of novel agents and advances of laboratory evaluation, the diagnosis and treatment of MM have been significantly improved. In this version, an anti-CD38 monoclonal antibody, Daratumumab, based regimens and related concerns were appended. The chimeric antigen receptor T cell (CAR-T) immunotherapy was updated in the section of relapse and refractory myeloma. Again, autologous stem cell transplantation (ASCT) is still the standard consolidation after front-line therapy for transplant candidates with MM.
多发性骨髓瘤（MM）是一种克隆性浆细胞疾病，是第二常见的血液系统恶性肿瘤。MM主要发生于老年人，目前仍无法治愈。随着新型药物的研发和实验室评估技术的进步，MM的诊断和治疗有了显著改善。在这一版中，增加了基于抗CD38单克隆抗体达雷妥尤单抗的治疗方案及相关注意事项。嵌合抗原受体T细胞（CAR-T）免疫疗法在复发难治性骨髓瘤部分进行了更新。同样，自体干细胞移植（ASCT）仍然是适合移植的MM患者一线治疗后标准的巩固治疗方法。
